RxDoctor Payments Data

Harold Yee, NP

Family · McAllen, TXNPI 1780248690

Payments from drug & device makers

$1,632in general payments, 2019–2025

Across 63 payments — averaging $25.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$635
  • Novartis$302
  • Cvrx, Inc.$156
  • Amgen$87
  • AstraZeneca$83
  • Pfizer$81
  • plus $287 from 6 others

What the payments were for

  • Food & beverage$1,632100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,632 in reported general payments places this provider in the 75th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$55,882
Medicare patients
313
Services billed
718

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan157$213,766
EliquisApixaban186$178,508
XareltoRivaroxaban113$156,365
FarxigaDapagliflozin Propanediol98$108,881
BrilintaTicagrelor33$38,637
JardianceEmpagliflozin30$33,177
VascepaIcosapent Ethyl41$19,255
Repatha SyringeEvolocumab19$14,787
Atorvastatin Calcium520$5,962
Amiodarone Hcl44$5,039
Metoprolol Succinate346$4,707
Ranolazine ErRanolazine40$4,204
Icosapent Ethyl13$3,924
Valsartan146$3,841
Labetalol Hcl57$2,570

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$302$213,766157 claims
PfizerEliquis$81$178,508186 claims
Johnson & JohnsonXarelto$71$156,365113 claims
AstraZenecaFarxiga, Brilinta$83$147,518131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 15,456 family providers in Texas.

Other family in McAllen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →